Mutations at the 3′ end of the DMD gene, which affect all DMD products, have been associated with a high prevalence of brain-related comorbidities [3, 4], impacting the cognitive domain, with intellectual disability (ID), difficulties in working memory and executive functions, the learning domain, the psychiatric domain, with conditions such as attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive compulsive disorder (OCD), and the emotional domain, including anxiety and depression [3–13]. This evidence concerns the gene DMD and major depressive disorder.